Citations

Clear

1320 citation(s) found for "Nguyen, Vi".

An Introductory Tutorial on Cardiovascular Pharmacogenetics for Healthcare Providers
Oni‐Orisan, Akinyemi , Tuteja, Sony , Hoffecker, Glenda , Smith, D. Max , Castrichini, Matteo , Crews, Kristine R. , Murphy, William A. , Nguyen, Nam , Huang, Yimei , Lteif, Christelle , Tantisira, Kelan G. , Cavallari, Larisa H. , Whirl‐Carrillo, Michelle , Duarte, Julio D. , Luzum, Jasmine A. , Nguyen, Nam H K , Friede, Kevin A , Aminkeng, Folefac , Voora, Deepak , Cavallari, Larisa H , Whirl-Carrillo, Michelle , Duarte, Julio D , Luzum, Jasmine A , Crews, Kristine R , Smith, D Max , Castrichini, Matteo , Oni-Orisan, Akinyemi , Murphy, William A.

Mayo Clinic

Clinical Pharmacology & Therapeutics | May 24, 2023 | Volume: 114 | Issue: 2 | Pages: 275-287

10.1002/cpt.2957 | PMID 37303270 Get It

Pharmacogenetics can improve clinical outcomes by reducing adverse drug effects and enhancing therapeutic efficacy for commonly used drugs that treat a wide range of cardiovascular diseases. One of the major barriers to the clinical implementation of cardiovascular pharmacogenetics is limited education on this field for current healthcare providers and students. The abundance of pharmacogenetic literature underscores its promise, but it can also be challenging to learn such a wealth of information. Moreover, current clinical recommendations for cardiovascular pharmacogenetics can be confusing because they are outdated, incomplete, or inconsistent. A myriad of misconceptions about the promise and feasibility of cardiovascular pharmacogenetics among healthcare providers also has halted clinical implementation. Therefore, the main goal of this tutorial is to provide introductory education on the use of cardiovascular pharmacogenetics in clinical practice. The target audience is any healthcare provider (or student) with patients that use or have indications for cardiovascular drugs. This tutorial is organized into the following 6 steps: (1) understand basic concepts in pharmacogenetics; (2) gain foundational knowledge of cardiovascular pharmacogenetics; (3) learn the different organizations that release cardiovascular pharmacogenetic guidelines and recommendations; (4) know the current cardiovascular drugs/drug classes to focus on clinically and the supporting evidence; (5) discuss an example patient case of cardiovascular pharmacogenetics; and (6) develop an appreciation for emerging areas in cardiovascular pharmacogenetics. Ultimately, improved education among healthcare providers on cardiovascular pharmacogenetics will lead to a greater understanding for its potential in improving outcomes for a leading cause of morbidity and mortality.
Effectiveness of HCC surveillance programs using multitarget blood test: A modeling study
Chhatwal, Jagpreet , Samur, Sumeyye , Yang, Ju Dong , Roberts, Lewis R. , Nguyen, Mindie H. , Ayer, Turgay , Parikh, Neehar D. , Singal, Amit G. , Ayer, Turgay , Parikh, Neehar D , Singal, Amit , Roberts, Lewis R , Yang, Ju Dong , Ozbay, A. Burak

Mayo Clinic

Hepatology Communications | May 19, 2023 | Volume: 7 | Issue: 6 | Pages: No page available

10.1097/hc9.0000000000000146 | PMID 37204402 Get It

Background: The effectiveness of ultrasound-based surveillance for HCC in patients with cirrhosis is limited by suboptimal sensitivity for early tumor detection and poor adherence. Emerging blood-based biomarkers have been proposed as an alternative surveillance strategy. We aimed to evaluate the comparative effectiveness of a multitarget HCC blood test (mt-HBT)—with and without improved adherence—against ultrasound-based HCC surveillance. Methods: We developed a Markov-based mathematical model that simulated a virtual trial in patients with compensated cirrhosis comparing potential surveillance strategies: biannual surveillance using ultrasound, ultrasound plus AFP, and mt-HBT with or without improved adherence (+10% increase). We used published data to inform underlying liver disease progression rates, HCC tumor growth patterns, performance characteristics of surveillance modalities, and efficacy of treatments. Primary outcomes of interest were the number of early-stage HCCs detected and life years gained. Results: Per 100,000 patients with cirrhosis, mt-HBT detected 1680 more early-stage HCCs than ultrasound alone and 350 more early-stage HCCs than ultrasound + AFP, yielding an additional 5720 and 1000 life years, respectively. mt-HBT with improved adherence detected 2200 more early-stage HCCs than ultrasound and 880 more early-stage HCCs than ultrasound + AFP, yielding an additional 8140 and 3420 life years, respectively. The number of screening tests needed to detect one HCC case was 139 with ultrasound, 122 with ultrasound + AFP, 119 with mt-HBT, and 124 with mt-HBT with improved adherence. Conclusions: mt-HBT is a promising alternative to ultrasound-based HCC surveillance, particularly given anticipated improved adherence with blood-based biomarkers could increase HCC surveillance effectiveness.
The Alzheimer's Disease Prediction Of Longitudinal Evolution (TADPOLE) Challenge: Results after 1 Year Follow-up
Bron, Esther E. , Toga, Arthur W. , Weiner, Michael W. , Barkhof, Frederik , Fox, Nick C. , Eshaghi, Arman , Toni, Tina, Salaterski, Marcin, Lunina, Veronika, Ansart, Manon , Lu, Pascal , Thompson, Wesley K., Nahon, Aviv, Levy, Yarden, Halbersberg, Dan, Cohen, Mariya, Liao, Huiling , Yu, Kaixian , Ismail, Aya, Wood, Timothy C. , Nguyen, Minh , Sun, Nanbo , Yeo, B.T. Thomas , Qi, Ke , Chen, Shiyang , Qiu, Deqiang , Buciuman, Ionut, Kelner, Alex, Rimocea, Denisa, Ourselin, Sébastien , Venkatraghavan, Vikram , Liu, Keli , Rabe, Christina, Manser, Paul T. , Howlett, James , Huang, Zhiyue , Mukherjee, Sach, Rouanet, Anaïs , Oriol, Javier de Velasco , Clemente, Edgar E. V., Estrada, Karol , Altmann, André , Stonnington, Cynthia M. , Wu, Jianfeng , Devadas, Vivek, Fourrier, Clémentine , Doshi, Jimit , Moore, Paul J. , Lyons, Terry , Ciszek, Robert, Jedynak, Bruno , Pandya, K., Engels, William R., Cole, Joseph B., Golland, Polina , Alexander, Daniel C. , Initiative, The Alzheimer's Disease Neuroimaging, Toga, Arthur W , Barkhof, Frederik , Fox, Nick C , Weiner, Michael W , Marinescu, Razvan Valentin , Oxtoby, Neil P. , Young, Alexandra L. , Durrleman, Stanley , Iddi, Samuel , Li, Dan , Donohue, Michael , Li, Tengfei , Zhu, Hongtu , Tamez‐Peña, José G. , Wood, Timothy, Bravo, Héctor Corrada , Feng, Jiashi , Chen, Gang , Qi, Ke, Pop, Raluca, Ghazi, Mostafa Mehdipour , Nielsen, Mads , Sørensen, Lauge , Hill, Steven M., Kiddle, Steven John , Taschler, Bernd , Tom, Brian D. M. , White, Simon Richard , Faux, Noel Garry , Sedai, Suman , Aksman, Leon , Wang, Yalin , Rakêt, Lars Lau , Sotiras, Aristeidis , Erus, Güray , Davatzikos, Christos , Vogel, Jacob W. , Doyle, Andrew , Tam, Angela , Diaz-Papkovich, Alex , Jammeh, Emmanuel , Koval, Igor , Gallacher, John , Tohka, Jussi , Pandya, Kruti, Bilgel, Murat , Engels, William, Cole, Joseph, Klein, Stefan , Initiative, The Alzheimer's Disease Neuroimaging

Mayo Clinic

Machine Learning for Biomedical Imaging | May 17, 2023 | Volume: 1 | Issue: December 2021 | Pages: 1-60

10.59275/j.melba.2021-2dcc Get It

Accurate prediction of progression in subjects at risk of Alzheimer's disease is crucial for enrolling the right subjects in clinical trials. However, a prospective comparison of state-of-the-art algorithms for predicting disease onset and progression is currently lacking. We present the findings of "The Alzheimer's Disease Prediction Of Longitudinal Evolution" (TADPOLE) Challenge, which compared the performance of 92 algorithms from 33 international teams at predicting the future trajectory of 219 individuals at risk of Alzheimer's disease. Challenge participants were required to make a prediction, for each month of a 5-year future time period, of three key outcomes: clinical diagnosis, Alzheimer's Disease Assessment Scale Cognitive Subdomain (ADAS-Cog13), and total volume of the ventricles. The methods used by challenge participants included multivariate linear regression, machine learning methods such as support vector machines and deep neural networks, as well as disease progression models. No single submission was best at predicting all three outcomes. For clinical diagnosis and ventricle volume prediction, the best algorithms strongly outperform simple baselines in predictive ability. However, for ADAS-Cog13 no single submitted prediction method was significantly better than random guesswork. Two ensemble methods based on taking the mean and median over all predictions, obtained top scores on almost all tasks. Better than average performance at diagnosis prediction was generally associated with the additional inclusion of features from cerebrospinal fluid (CSF) samples and diffusion tensor imaging (DTI). On the other hand, better performance at ventricle volume prediction was associated with inclusion of summary statistics, such as the slope or maxima/minima of patient-specific biomarkers. On a limited, cross-sectional subset of the data emulating clinical trials, performance of the best algorithms at predicting clinical diagnosis decreased only slightly (2 percentage points) compared to the full longitudinal dataset. The submission system remains open via the website https://tadpole.grand-challenge.org, while TADPOLE SHARE (https://tadpole-share.github.io/) collates code for submissions. TADPOLE's unique results suggest that current prediction algorithms provide sufficient accuracy to exploit biomarkers related to clinical diagnosis and ventricle volume, for cohort refinement in clinical trials for Alzheimer's disease. However, results call into question the usage of cognitive test scores for patient selection and as a primary endpoint in clinical trials.
A Systematic Review and Meta-analysis of Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection With Mega Dose Vitamin D
Nguyen, M., Bugazia, S., Mashina, Radwan, Ajala, Mohaned M., Sakr, Yara , Kamal, I., Hagrass, Abdulrahman Ibrahim , Fathallah, Ahmed Hashem , Mashina, M., Bugazia, S. , Ragab, Khaled Mohamed , Singh, Aditi

Mayo Clinic

C66. VIRAL INFECTIONS, COVID, AND BEYOND | May 1, 2023 | Volume: No volume available | Issue: No issue available | Pages: A5604-A5604

10.1164/ajrccm-conference.2023.207.1_meetingabstracts.a5604 Get It

Inclusion of Comorbidities and Prognosis in U.S. States' Triage Plans During COVID-19
Ennis, Jackson S, Nguyen, N.V. , Kramer, D.B., Smith, Andrew , Sulmasy, Dan, Tilburt, Jon C. , DeMartino, Erin S. , Ennis, Jackson S. , Riggan, Kirsten A. , Wolf, Susan M.

Mayo Clinic

D93. CLINICAL AND TRANSLATIONAL STUDIES OF COVID-19 CRITICAL ILLNESS | May 1, 2023 | Volume: No volume available | Issue: No issue available | Pages: A6554-A6554

10.1164/ajrccm-conference.2023.207.1_meetingabstracts.a6554 Get It

The Role of Allograft Nephrectomy in the Failing Kidney Transplant
Budhiraja, Pooja , Nguyen, Michelle , Heilman, Raymond L. , Budhiraja, Pooja , Kaplan, Bruce

Mayo Clinic

Transplantation | May 1, 2023 | Volume: 107 | Issue: 12 | Pages: 2486-2496

10.1097/tp.0000000000004625 | PMID 37122077 Get It

Patients with failed renal allografts have associated increased morbidity and mortality. The individualization of immunosuppression taper is the key element in managing these patients to avoid graft intolerance and sensitization while balancing the risk of continued immunosuppression. Most patients with uncomplicated chronic allograft failure do not require allograft nephrectomy (AN), and there is no clear evidence that it improves outcomes. The AN procedure is associated with variable morbidity and mortality. It is reserved mainly for early technical graft failure or in symptomatic cases associated with allograft infection, malignancy, or graft intolerance syndrome. It may also be considered in those who cannot tolerate immunosuppression and are at high risk for graft intolerance. AN has been associated with an increased risk of sensitization due to inflammatory response from surgery, immunosuppression withdrawal with allograft failure, and retained endovascular tissue. Although it is presumed that for-cause AN after transplant failure is associated with sensitization, it remains unclear whether elective AN in patients who remain on immunotherapy may prevent sensitization. The current practice of immunosuppression taper has not been shown to prevent sensitization or increase infection risk, but current literature is limited by selection bias and the absence of medication adherence data. We discuss the management of failed allografts based on retransplant candidacy, wait times, risk of graft intolerance syndrome, and immunosuppression side effects. Many unanswered questions remain, and future prospective randomized trials are needed to help guide evidence-based management.
Microfluidic ‘Brain-on Chip’ Systems to Supplement Neurological Practice: Development, Applications and Considerations
Jarrah, Ryan , Nathani, Karim Rizwan , Bhandarkar, Shaan , Ezeudu, Chibuze S., Nguyen, Ryan T. , Amare, Abrham, Aljameey, Usama A., Jarrah, Sabrina I., Bhandarkar, Archis R. , Fiani, Brian , Nathani, Karim Rizwan , Nguyen, Ryan T

Mayo Clinic

Regenerative Medicine | April 26, 2023 | Volume: 18 | Issue: 5 | Pages: 413-423

10.2217/rme-2022-0212 | PMID 37125510 Get It

εγ-Thalassemia, a New Hemoglobinopathy Category
Oliveira, Jennifer L. , Thompson, Christineil , Saravanaperumal, Siva Arumugam , Koganti, Tejaswi , Jenkinson, Garrett , Hein, Molly S., Kohorst, Mira A. , Hasadsri, Linda , Nguyen, Phuong L., Matern, Dietrich , Kipp, Benjamin R. , Klee, Eric W. , Wieben, Eric D. , Hoyer, James D., Rangan, Aruna , Thompson, Christineil H

Mayo Clinic

Clinical Chemistry | April 22, 2023 | Volume: 69 | Issue: 7 | Pages: 711-717

10.1093/clinchem/hvad038 | PMID 37086467 Get It

Abstract Background Large β-globin gene cluster deletions (hereditary persistence of fetal hemoglobin [Hb] or β-, δβ-, γδβ-, and ϵγδβ-thalassemia), are associated with widely disparate phenotypes, including variable degrees of microcytic anemia and Hb F levels. When present, increased Hb A2 is used as a surrogate marker for β-thalassemia. Notably, ϵγδβ-thalassemias lack the essential regulatory locus control region (LCR) and cause severe transient perinatal anemia but normal newborn screen (NBS) results and Hb A2 levels. Herein, we report a novel deletion of the ϵ, Aγ, Gγ, and ψβ loci with intact LCR, δ-, and β-regions in 2 women and newborn twins. Methods Capillary electrophoresis (CE), high-performance liquid chromatography (HPLC), DNA sequencing, multiplex ligation-dependent probe amplification (MLPA), gap-polymerase chain reaction (gap-PCR), and long-read sequencing (LRS) were performed. Results NBS showed an Hb A > Hb F pattern for both twins. At 20 months, Hb A2 was increased similarly to that in the mother and an unrelated woman. Unexplained microcytosis was absent and the twins lacked severe neonatal anemia. MLPA, LRS, and gap-PCR confirmed a 32 599 base pair deletion of ϵ (HBE1) through ψβ (HBBP1) loci. Conclusions This deletion represents a hemoglobinopathy category with a distinct phenotype that has not been previously described, an ϵγ-thalassemia. Both the NBS Hb A > F pattern and the subsequent increased Hb A2 without microcytosis are unusual. A similar deletion should be considered when this pattern is encountered and appropriate test methods selected for detection. Knowledge of the clinical impact of this new category will improve genetic counselling, with distinction from the severe transient anemia associated with ϵγδβ-thalassemia.
Navigating Practice Issues Related to the Unsatisfactory Cervicovaginal Papanicolaou Test: Survey Results of Laboratories Participating in the 2020 College of American Pathologists PAP Education Program
Booth, Christine N. , Souers, Rhona J., Tabbara, Sana, Roberson, Janie, Henry, Michael , Sundling, Kaitlin E. , Goodrich, Kelly, Henry, Michael R, Goyal, Abha , Nguyen, Lananh

Mayo Clinic

Archives of Pathology & Laboratory Medicine | April 19, 2023 | Volume: 148 | Issue: 1 | Pages: 48-54

10.5858/arpa.2022-0330-cp | PMID 37074866 Get It

Context.— Unsatisfactory Papanicolaou (Pap) tests pose a unique set of challenges to the laboratory with regard to their processing, review, reporting, and performance of human papillomavirus (HPV) testing. There are no standardized guidelines for the review process and handling of unsatisfactory Pap tests. Objective.— To assess the current practice patterns regarding various aspects of the unsatisfactory Pap test, from processing to reporting, across laboratories worldwide. Design.— A supplemental questionnaire was mailed to laboratories participating in the 2020 College of American Pathologists (CAP) Gynecologic Cytopathology (PAP Education) Program, requesting data regarding the unsatisfactory Pap test. Results.— Of 1520 participating laboratories, 619 (40.7%) responded, and the responses of 577 laboratories were included for further analysis. Only 64.6% (373 of 577) laboratories used the unsatisfactory Pap test criteria as specified by the 2014 Bethesda System. About three-quarters of the respondents (433 of 576; 75.2%) routinely rescreened unsatisfactory Pap tests. Routine repreparation of such Pap tests was performed by 54.9% (316 of 576) of laboratories, and 52.0% (293 of 563) used glacial acetic acid for repreparing excessively bloody specimens. HPV test results were reported for unsatisfactory Pap tests, always or sometimes, by 62.4% (353 of 566) of respondents. Conclusions.— This CAP survey reveals important information regarding the practice patterns pertaining to several aspects of the unsatisfactory Pap test. It also provides valuable insight into the quality assurance measures that can be implemented for such tests. Future studies can further aid in the standardization of all components of the handling of unsatisfactory Pap tests for overall quality improvement.